David Rosenthal, MD
Associate Professor of Medicine (General Medicine)Cards
About
Research
Publications
2025
Proton versus photon radiotherapy for patients with oropharyngeal cancer in the USA: a multicentre, randomised, open-label, non-inferiority phase 3 trial
Frank S, Busse P, Lee J, Rosenthal D, Hernandez M, Swanson D, Garden A, Gunn G, Patel S, Snider J, J D, Molitoris J, Lee N, Parvathaneni U, McDonald M, Kalman N, Lin A, Mohammed N, Henson C, Hyde C, Bajaj G, Katz S, Dagan R, Morrison W, Reddy J, Fuller C, Shah S, Phan J, Chronowski G, Mayo L, Sturgis E, Ferrarotto R, Zhu X, Zhang X, Wang L, Hutcheson K, El-Naggar A, Moreno A, Lee A, Spiotto M, Gross N, Lai S, Liao J, Paly J, Liao Z, Foote R, Consortium T, Bates J, Chambers M, Chun S, Kaiser A, Lester S, Lukens J, McGee L, Neben-Wittich M, Nguyen Q, Routman D, Schlembach P, Skinner H, Soike M, Rwigema J, Wiederhold L, Blanchard P, Choi I, Koong A, Langendijk H, Mohan R, Carlson B, Mapps A, Sarmiento J, Teferra M, Bosch W, Followill D, Taylor P, Fuentes S, Ning M, Toumazis I, Wogan C, De Gracia B, Fink K, Grippin A, Ma J, Pettersen E, Sareyeldin R, Cronin C, Muise S, Johnson M, Pyfferoen K, Tranby B, Leonard J, Watkin S, Eggleston C, Barrow B, Wolcott J, Antonio J, Brand J, Cleverdon A, Drake M, Peters E, Small C, Clark K, Holder R. Proton versus photon radiotherapy for patients with oropharyngeal cancer in the USA: a multicentre, randomised, open-label, non-inferiority phase 3 trial. The Lancet 2025 PMID: 41391462, DOI: 10.1016/s0140-6736(25)01962-2.Peer-Reviewed Original ResearchIntensity-modulated radiation therapy groupIMPT groupIntensity-modulated proton therapyIntensity-modulated radiation therapyProgression-free survivalOropharyngeal cancerPhase 3 trialPhoton radiotherapyOpen-labelSystemic therapyProton therapyNon-inferiority phase 3 trialStandard-of-care treatment optionEastern Cooperative Oncology Group performance statusInstitutional multidisciplinary tumour boardProgression-free survival ratesIntention-to-treat populationSurvival rateConcurrent systemic therapyDe-intensify treatmentDisease control rateIV oropharyngeal cancerTreatment-related deathsTreated with radiotherapyMD Anderson Cancer CenterTreatment Interruption and Outcomes in Head and Neck Cancer
Gharzai L, Morris E, Schipper M, Kidwell K, Nguyen-Tân P, Rosenthal D, Gillison M, Jordan R, Garden A, Koyfman S, Caudell J, Blakaj D, Dunlap N, Krempl G, Longo J, Jones C, Gensheimer M, Galloway T, DeMora L, Le Q, Shah J, Suresh K, Mierzwa M. Treatment Interruption and Outcomes in Head and Neck Cancer. JAMA Otolaryngology - Head & Neck Surgery 2025, 152 PMID: 41343184, PMCID: PMC12679426, DOI: 10.1001/jamaoto.2025.4203.Peer-Reviewed Original ResearchHead and neck squamous cell carcinomaLocoregional failureRT interruptionOverall survivalP16 statusTreatment interruptionHazard ratioAssociated with poor oncological outcomesNeck squamous cell carcinomaHead and neck cancerP16-negative cancersHigher-stage diseaseTreated with RTPoor oncological outcomesSquamous cell carcinomaCox proportional hazards modelsAssociated with hazard ratiosRandomized clinical trialsSecondary analysisProportional hazards modelNon-T4Oncological outcomesTumor characteristicsRetrospective reviewCell carcinomaInternational guidelines for the delineation of the postoperative clinical target volumes (CTV) for parotid and submandibular gland cancers
Biau J, Nutting C, Langendijk J, Thariat J, O’Sullivan B, Cacicedo J, Blanchard P, Lee N, McBride S, Caudell J, Rosenthal D, Yom S, McDowell L, Chua M, Bourhis J, Grégoire V, Lapeyre M. International guidelines for the delineation of the postoperative clinical target volumes (CTV) for parotid and submandibular gland cancers. Radiotherapy And Oncology 2025, 214: 111317. PMID: 41317999, DOI: 10.1016/j.radonc.2025.111317.Peer-Reviewed Original ResearchConceptsClinical target volumeSubmandibular gland cancerPost-operative radiotherapyPerineural invasionTarget volumeClinical target volume delineationNodal clinical target volumePostoperative clinical target volumeNatural historyPatient-specific risk factorsEra of IMRTLocal tumor spreadSalivary gland cancerImaging-pathology correlationConsensus-based guidelinesCTV delineationTumor extensionRadiation oncologistsTumor spreadCTV-pConsensus guidelinesConformal techniquePrimary siteConsensus statementRisk factorsPatient-reported outcomes after ipsilateral radiation therapy for N2b tonsillar squamous cell carcinoma
Abana C, Garden A, Brandon Gunn G, Chronowski G, Mohamed A, Frankart A, Geier N, Bahig H, Barbon C, Hutcheson K, Takiar V, Fuller C, Frank S, Rosenthal D, Phan J. Patient-reported outcomes after ipsilateral radiation therapy for N2b tonsillar squamous cell carcinoma. Discover Oncology 2025, 16: 2165. PMID: 41288848, PMCID: PMC12647442, DOI: 10.1007/s12672-025-03896-z.Peer-Reviewed Original ResearchSquamous cell carcinomaTonsillar squamous cell carcinomaPatient-reported outcomesRadiation therapyHead and neckCell carcinomaDry mouthTreatment volumeHuman papillomavirus-positive diseaseHead and neck symptomsTonsil squamous cell carcinomaPatient-reported outcomes of patientsHead and neck cancerPhysician-assessed toxicityResultsForty-eight patientsAssociated with lower ratesAJCC-7N2b diseaseNeck RTExtranodal extensionSystemic therapyCore symptomsNeck cancerGeneral activityInterference symptomsPerspective: Radiotherapy and Body Composition: Unmet Needs in Low- and Middle-Income Countries
Murphy-Alford A, Grossberg A, Baracos V, Barbar M, Bauer J, Bennett J, Fidarova E, Fuller C, Löser A, Moreno A, Patra A, Puttaswamy D, Rosenthal D, Schoeman J, Anacak Y. Perspective: Radiotherapy and Body Composition: Unmet Needs in Low- and Middle-Income Countries. Advances In Nutrition 2025, 17: 100563. PMID: 41242549, DOI: 10.1016/j.advnut.2025.100563.Peer-Reviewed Original ResearchPatient's nutritional statusMiddle-income countriesRates of co-morbiditiesAdverse clinical outcomesRadiotherapy patientsTreatment toleranceDelayed DiagnosisClinical outcomesVulnerability of cancer patientsCancer patientsCo-morbiditiesMuscle lossNutritional careBody compositionNutritional statusCancer treatmentPatientsRadiotherapyHigh-income countriesHeightened vulnerabilityEvidence gapsUnmet needsTreatmentOutcomesMiddle-incomeDesigning an Electronic Patient-Reported Outcomes Information Infrastructure Supported by the RE-AIM Implementation Framework
Moreno A, Peek A, Shein T, Shook K, Ali S, Humbert-Vidan L, Chen A, Lango M, Lee A, Spiotto M, Morrison W, Garden A, Phan J, Frank S, Hutcheson K, Rosenthal D, Fuller C, Gunn G. Designing an Electronic Patient-Reported Outcomes Information Infrastructure Supported by the RE-AIM Implementation Framework. Advances In Cancer Education And Quality Improvement 2025, 1 DOI: 10.52519/aceqi.25.1.2.a6.Peer-Reviewed Original ResearchPatient-reported outcomesRE-AIMElectronic PROsImplementation of electronic patient-reported outcomesRE-AIM implementation frameworkReach-Effectiveness-Adoption-Implementation-MaintenanceElectronic patient-reported outcomesRE-AIM metricsElectronic health recordsInformation infrastructureHead and Neck ModuleQuality of lifeEPRO dataEHR systemsHealth recordsClinical staffOncology clinicImplementation evaluationProgram facilitatorsRadiation oncology clinicInformation toolsEHR platformCompliance rateMDASI-HNNeck ModuleOutcomes in Patients with Benign Tumors of the Head and Neck Treated with LINAC-Based Stereotactic Body Radiation Therapy
Patel A, Lee A, Wang H, Wang X, Moreno A, Reddy J, Spiotto M, Rosenthal D, Raza S, DeMonte F, Gidley P, Nader M, Su S, Hanna E, Garden A, Phan J. Outcomes in Patients with Benign Tumors of the Head and Neck Treated with LINAC-Based Stereotactic Body Radiation Therapy. International Journal Of Radiation Oncology • Biology • Physics 2025, 123: e370-e371. DOI: 10.1016/j.ijrobp.2025.06.2343.Peer-Reviewed Original ResearchStereotactic body radiation therapyBenign head and neck tumorsHead and neck tumorsGross diseaseRadiation therapyNeck tumorsLocal controlCranial nervesSurgical resectionOverall survivalPre-treatment symptomsBenign tumorsRadiographic evidenceAssociated with high morbidity ratesMedian target volumeGrade 2 nauseaCranial nerve involvementMedian Follow-UpHead and neckNon-vestibular schwannomasEffective treatment optionOptimal local controlHigh morbidity ratesCN injuryMedian followDevelopment and Validation of a Digital Pathology-Based, Multimodal Artificial Intelligence (MMAI) Biomarker in Patients with Head and Neck Cancer
Chinn S, Ma X, Tierney M, Moatadelro A, Rosten E, Rosenthal D, Caudell J, Dunlap N, Jones C, Woody N, Galloway T, Nguyen F, Raben A, Shenouda G, Blakaj D, Firat S, Machtay M, Le Q, Schipper M, Yom S. Development and Validation of a Digital Pathology-Based, Multimodal Artificial Intelligence (MMAI) Biomarker in Patients with Head and Neck Cancer. International Journal Of Radiation Oncology • Biology • Physics 2025, 123: s72-s73. DOI: 10.1016/j.ijrobp.2025.06.1087.Peer-Reviewed Original ResearchHead and neck cancerRT-treated patientsProgression-free survivalDisease-free survivalPrimary tumor siteOverall survivalAJCC stageTumor siteNeck cancerLocoregionally advanced head and neck cancerAdvanced head and neck cancerC-indicesOutcome of head and neck cancerSurgically-treated patientsPhase III trialsHarrell's C-indicesIndependent of stageCox proportional hazards modelsClinical outcome of head and neck cancerProportional hazards modelHPV statusIII trialsTumor specimensSurgery-basedPrognostic classifierSevere Sleep-Related Symptoms at Start of Radiotherapy Predict Poorer Survival in Oropharyngeal Cancer: Results from a Longitudinal Symptom Cohort
Floyd W, Gaur R, Dede C, Carevic G, Rosenthal D, Garden A, Gunn G, Frank S, Lai S, Hutcheson K, Moreno A, Faiz S, Fuller C. Severe Sleep-Related Symptoms at Start of Radiotherapy Predict Poorer Survival in Oropharyngeal Cancer: Results from a Longitudinal Symptom Cohort. International Journal Of Radiation Oncology • Biology • Physics 2025, 123: e335. DOI: 10.1016/j.ijrobp.2025.06.2267.Peer-Reviewed Original ResearchSleep related symptomsAssociated with worse overall survivalOropharyngeal cancerRT startOverall survivalCox proportional hazards modelsSleep-related symptomsProportional hazards modelPatients treated with curative-intent RTRelated symptomsAssociated with significantly worse overall survivalKaplan-Meier/log-rank testsAssociated with worse OSSleep disturbanceSignificantly worse overall survivalMultivariate Cox proportional hazards modelHead and neck cancerCurative-intent RTMedian RT doseOropharyngeal cancer patientsHazards modelResults Median ageT1-T2 diseaseMonths post-RTMD Anderson Symptom Inventory-Head1659P Updated pathologic responses from a pilot phase II trial of neoadjuvant immunotherapy for stage II-IV resectable cutaneous squamous cell carcinoma of the head and neck (CSCC-HN)
Amit M, Ferrarotto R, Nagarajan P, Li G, Yuan Y, Morrison W, Rosenthal D, de Sousa L, Johnson F, Diaz E, Gidley P, Lewis C, Myers J, Gross N. 1659P Updated pathologic responses from a pilot phase II trial of neoadjuvant immunotherapy for stage II-IV resectable cutaneous squamous cell carcinoma of the head and neck (CSCC-HN). Annals Of Oncology 2025, 36: s982. DOI: 10.1016/j.annonc.2025.08.2287.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
Clinical Care
Overview
David Rosenthal, MD, is a primary care physician who specializes in general internal medicine. He focuses on providing comprehensive health care services, especially to populations such as veterans experiencing homelessness.
As an associate professor at Yale School of Medicine, Dr. Rosenthal’s research interests include health care services for vulnerable populations and health informatics, aiming to improve accessibility and efficacy of care for all. He has developed and implemented innovative technology solutions to enhance patient care, including mobile apps for substance use disorder management.
Dr. Rosenthal received his medical training from Northwestern University Feinberg School of Medicine, followed by an internship and primary care residency at Brigham and Women's Hospital. He has been recognized by the Aspen Institute as a Health Innovator Fellow for his contributions to public health and innovation.
Clinical Specialties
General Internal Medicine; Internal Medicine
Board Certifications
Internal Medicine
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2012
News & Links
News
- June 11, 2025
Yale Internal Medicine Faculty and Trainees Receive Outstanding Teaching Awards
- March 11, 2025
Yale Department of Internal Medicine Faculty Promotions and Appointments (March 2025)
- January 15, 2025
Student Auction Supports New Haven Nonprofits
- July 08, 2024
Dean Ranney Joins Other Public Health Thought Leaders at Aspen Ideas: Health Festival
Get In Touch
Contacts
Mailing Address
General Internal Medicine
150 Sargent Dr
New Haven, CT 06511
United States